Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 4

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 4
---
6) Notes to Condensed Interim Consolidated Financial Statements              |     | 23 |
| (Significant Uncertainty Regarding Going Concern Assumption)                  |     | 23 |
| (Material Accounting Policies)                                                |     | 23 |
| (Operating Segment Information)                                               |     | 23 |
| (Significant Subsequent Events)                                               |     | 23 |
| [Financial Appendix]                                                          |     |    |

<div align='center'>1</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

1. Financial Highlights for the Six-month Period Ended September 30, 2025

### (1) Business Performance
(i) Consolidated Financial Results (April 1 to September 30, 2025)

|                                                                                  |     |            |     |         |     |           |     |         |     |          |     |        |     |       |   |     |     |       | Billion JPY or percentage |
|                                                                                  |     | FY2024 H1  |     |         |     | FY2025 H1 |     |         |     | AER      |     |        |     |       |   | CER |     |       |                           |
|                                                                                  |     | JPY Change |     |         |     | % Change  |     |         |     | % Change |     |        |     |       |   |     |     |       |                           |
| Revenue                                                                          |     |            |     | 2,384.0 |     |           |     | 2,219.5 |     |          |     | -164.5 |     |  -6.9 | % |     |     |  -3.9 | %                         |
| Cost of sales                                                                    |     |            |     |  -781.3 |     |           |     |  -764.7 |     |          |     |   16.5 |     |  -2.1 | % |     |     |   0.9 | %                         |
| Selling, general and administrative expenses                                     |     |            |     |  -538.3 |     |           |     |  -509.4 |     |          |     |   28.9 |     |  -5.4 | % |